Cart
sales@molnova.com
Mbx2329
CAS No. 1438272-42-4
Mbx2329( —— )
Catalog No. M23605 CAS No. 1438272-42-4
MBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 133 | In Stock |
|
| 10MG | 203 | In Stock |
|
| 25MG | 410 | In Stock |
|
| 50MG | 605 | In Stock |
|
| 100MG | 860 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMbx2329
-
NoteResearch use only, not for human use.
-
Brief DescriptionMBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.
-
DescriptionMBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
RecptorAntiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1438272-42-4
-
Formula Weight283.84
-
Molecular FormulaC16H26ClNO
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (880.78 mM)
-
SMILESCCC1=CC=CC=C1OCCN2CCCCCC2.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Basu A , Antanasijevic A , Wang M , et al. New Small Molecule Entry Inhibitors Targeting Hemagglutinin-Mediated Influenza A Virus Fusion[J]. Journal of Virology, 2014, 88(3):1447-60.
molnova catalog
related products
-
Epetirimod
Epetirimod (S-30563) is a small molecule immunomodulator with antitumor and anti-infective activity for the study of papillomavirus infections.
-
15-Dicaffeoylquinic ...
15-Dicaffeoylquinic acid has neuroprotective and antioxidant effects it can inhibition of GSK3β as well as the modulation of Bcl-2/Bax.
-
EIDD-2749
EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.
